by Robert Rogoyski, J.D.
7 Colum. Sci. & Tech. L. Rev. 4 (2006) (Published April 15, 2006)
For more than 20 years, the marketing exclusivity provision of the Orphan Drug Act has been hailed as a key component of the incentive for the United States’ pharmaceutical industry to develop drugs for rare disorders; this is the Official Story of the ODA. In this paper, I argue that the Official Story is a myth. Rather, the real engine for the development of drugs to treat rare disorders is the patent system.
About the Author
Robert Rogoyski: J.D. cum laude, Harvard Law School, 2005.
For proper legal citation of this document, please cite to the following URL: http://www.stlr.org/cite.cgi?volume=7&article=4. The URL that currently appears in your browser’s location toolbar is incorrect. For more information on Bluebook citation of internet sources, click here.